NY Prostate Cancer Conference - A. Vickers - Session 1: Traditional statistical methods for evaluating prediction models are uninformative: towards a decision analytic approach
The document discusses the limitations of traditional statistical methods like sensitivity, specificity, and AUC for evaluating prediction models and tests. It argues that these metrics do not consider clinical consequences and do not help clinicians determine which test to use. The document introduces decision curve analysis as an alternative that incorporates the relative importance of sensitivity vs specificity through a threshold probability parameter. Decision curve analysis calculates net benefit across a range of threshold probabilities to assess clinical value, addressing limitations of traditional metrics.
Development and evaluation of prediction models: pitfalls and solutions (Part...BenVanCalster
Slides for the statistics in practice session for the Biometrisches Kolloquium (organized by the Deutsche Region der Internationalen Biometrischen Gesellschaft), 16 March 2021.
Part I from Maarten van Smeden: https://www.slideshare.net/MaartenvanSmeden/development-and-evaluation-of-prediction-models-pitfalls-and-solutions
Are you interested in learning how to prevent hospital readmissions for your diabetic population? It is a popular belief that measuring blood glucose for your diabetic population is the most predictive variable in determining a hospital readmission for a diabetic. However, many providers of care simply do not perform the test on known diabetic patients. This study takes a look at an advanced analytic method that works within the current healthcare providers workflow to looks to identify the likelihood of a future 30-day unplanned readmission before hospital discharge.
A comment in Nature, signed by over 800 researchers, called for a rise up against statistical significance. This was followed by a special issue of The American Statistician aimed at halting the use of the term "statistically significant", and new guidelines for statistical reporting in the New England Journal of Medicine. These slides discuss the broader context of the "p-value crisis" and alternatives for communicating the conclusions after statistical analyses.
Target audience: Medical researchers; Scientists involved in conducting or interpreting analyses and communicating the results of scientific research, as well as readers of scientific publications.
Learning objectives:
To understand the context of the reproducibility crisis in medical research.
To learn about problems with p-values and alternatives to report findings.
To understand how (not) to interpret significant and insignificant findings.
To learn how to communicate research findings in a modest, thoughtful, and transparent way.
5 essential steps for sample size determination in clinical trials slidesharenQuery
In this free webinar hosted by nQuery Researcher & Statistician Eimear Keyes, we map out the 5 essential steps for sample size determination in clinical trials. At each step, Eimear will highlight the important function it plays and how to avoid the errors that will negatively impact your sample size determination and therefore your study.
Watch the Video: https://www.statsols.com/webinar/the-5-essential-steps-for-sample-size-determination
Development and evaluation of prediction models: pitfalls and solutions (Part...BenVanCalster
Slides for the statistics in practice session for the Biometrisches Kolloquium (organized by the Deutsche Region der Internationalen Biometrischen Gesellschaft), 16 March 2021.
Part I from Maarten van Smeden: https://www.slideshare.net/MaartenvanSmeden/development-and-evaluation-of-prediction-models-pitfalls-and-solutions
Are you interested in learning how to prevent hospital readmissions for your diabetic population? It is a popular belief that measuring blood glucose for your diabetic population is the most predictive variable in determining a hospital readmission for a diabetic. However, many providers of care simply do not perform the test on known diabetic patients. This study takes a look at an advanced analytic method that works within the current healthcare providers workflow to looks to identify the likelihood of a future 30-day unplanned readmission before hospital discharge.
A comment in Nature, signed by over 800 researchers, called for a rise up against statistical significance. This was followed by a special issue of The American Statistician aimed at halting the use of the term "statistically significant", and new guidelines for statistical reporting in the New England Journal of Medicine. These slides discuss the broader context of the "p-value crisis" and alternatives for communicating the conclusions after statistical analyses.
Target audience: Medical researchers; Scientists involved in conducting or interpreting analyses and communicating the results of scientific research, as well as readers of scientific publications.
Learning objectives:
To understand the context of the reproducibility crisis in medical research.
To learn about problems with p-values and alternatives to report findings.
To understand how (not) to interpret significant and insignificant findings.
To learn how to communicate research findings in a modest, thoughtful, and transparent way.
5 essential steps for sample size determination in clinical trials slidesharenQuery
In this free webinar hosted by nQuery Researcher & Statistician Eimear Keyes, we map out the 5 essential steps for sample size determination in clinical trials. At each step, Eimear will highlight the important function it plays and how to avoid the errors that will negatively impact your sample size determination and therefore your study.
Watch the Video: https://www.statsols.com/webinar/the-5-essential-steps-for-sample-size-determination
Medical Decision Making associated with Clinical test interpretations. Depending on the situation one should get a second test to confirm the result of the first one; or one should move on to the treatment phase.
Practical Methods To Overcome Sample Size ChallengesnQuery
Watch the video at: https://www.statsols.com/webinars/practical-methods-to-overcome-sample-size-challenges
In this webinar hosted by Ronan Fitzpatrick - Head of Statistics and nQuery Lead Researcher at Statsols - we will examine some of the most common practical challenges you will experience while calculating sample size for your study. These challenges will be split into two categories:
1. Overcoming Sample Size Calculation Challenges
(Survival Analysis Example)
We will examine practical methods to overcome common sample size calculation issues by focusing in on one of the more complex areas for sample size determination; Survival analysis. We will cover difficulties and potential issues surrounding challenges such as:
Drop Out: How to deal with expected dropouts or censoring. We compare the simple loss-to-follow-up method and integrating a dropout process into the sample size model?
Planning Uncertainty: How best to deal with the inevitable uncertainty at the planning stage? We examine how best to apply a sensitivity analysis and Bayesian approaches to explore the uncertainty in your sample size calculations.
Choosing the Effect Size: Various approaches and interpretations exist for how to find the effect size value. We examine those contrasting interpretations and determine the best method and also how to deal with parameterization options.
2. Overcoming Study Design Challenges
(Vaccine Efficacy Example)
The Randomised Controlled Trial (RCT) is considered the gold standard in trial design in drug development. However, there are often practical impediments which mean that adjustments or pragmatic approaches are needed for some trials and studies.
We will examine practical methods how to overcome common study design challenges and how these affect your sample size calculations. In this webinar, we will use common issues in vaccine study design to examine difficulties surrounding issues such as:
Case-Control Analysis: We will examine how to deal with study constraints and how to deal with analyses done during an observational study.
Alternative Randomization Methods: How best to address randomization in your vaccine trial design when full randomization is difficult, expensive or impractical. We examine how sample size calculations are affected with cluster or Mendelian randomization.
Rare Events: How does an outcome being rare affect the types of study design and statistical methods chosen in your study.
Combination of informative biomarkers in small pilot studies and estimation ...LEGATO project
Background:
Biomarker candidates are defined as measurable molecules found in biological media. According to Biomarkers Definitions Working Group, 2001, biomarkers cover a rather wide range of parameters. Recently, biomarkers are used widely in medical researches, where single biomarkers may not possess the desired cause-effect association for disease classification and outcome prediction. Therefore the efforts of the researchers currently is to combine biomarkers. By new technologies like microarrays, next generation sequencing and mass spectrometry, researchers can obtain many biomarker candidates that can exceed tens of thousands. To avoid wasting money and time, it is suggested to control the number of patients strictly. However, pilot studies usually have low statistical power which reduces the chance of detecting a true effect .
Minimizing Risk In Phase II and III Sample Size CalculationnQuery
[ Watch Webinar: http://bit.ly/2thIgmi ]. In this free webinar, Head of Statistics at Statsols, Ronan Fitzpatrick, addresses the issues of reducing risk in Phase II/III sample size calculations. Topics covered will include:
Sample Size Determination For Different Trial Designs
Bayesian Sample Size Determination
Sample Size For Survival Analysis
& more
Large amounts of heterogeneous medical data have become available in various healthcare organizations (payers, providers, pharmaceuticals). Those data could be an enabling resource for deriving insights for improving care delivery and reducing waste. The enormity and complexity of these datasets present great challenges in analyses and subsequent applications to a practical clinical environment. More details are available here http://dmkd.cs.wayne.edu/TUTORIAL/Healthcare/
Sample size calculation in medical researchKannan Iyanar
A short description on estimation of sample size in health care research. It describes the basic concepts in sample size estimation and various important formulae used for it.
Workshop on "Building Successful Pipelines for Predictive Analytics in Healthcare" delivered by Danielle Belgrave, PhD, Researcher at Microsoft Research, Cambridge, UK.
Medical Decision Making associated with Clinical test interpretations. Depending on the situation one should get a second test to confirm the result of the first one; or one should move on to the treatment phase.
Practical Methods To Overcome Sample Size ChallengesnQuery
Watch the video at: https://www.statsols.com/webinars/practical-methods-to-overcome-sample-size-challenges
In this webinar hosted by Ronan Fitzpatrick - Head of Statistics and nQuery Lead Researcher at Statsols - we will examine some of the most common practical challenges you will experience while calculating sample size for your study. These challenges will be split into two categories:
1. Overcoming Sample Size Calculation Challenges
(Survival Analysis Example)
We will examine practical methods to overcome common sample size calculation issues by focusing in on one of the more complex areas for sample size determination; Survival analysis. We will cover difficulties and potential issues surrounding challenges such as:
Drop Out: How to deal with expected dropouts or censoring. We compare the simple loss-to-follow-up method and integrating a dropout process into the sample size model?
Planning Uncertainty: How best to deal with the inevitable uncertainty at the planning stage? We examine how best to apply a sensitivity analysis and Bayesian approaches to explore the uncertainty in your sample size calculations.
Choosing the Effect Size: Various approaches and interpretations exist for how to find the effect size value. We examine those contrasting interpretations and determine the best method and also how to deal with parameterization options.
2. Overcoming Study Design Challenges
(Vaccine Efficacy Example)
The Randomised Controlled Trial (RCT) is considered the gold standard in trial design in drug development. However, there are often practical impediments which mean that adjustments or pragmatic approaches are needed for some trials and studies.
We will examine practical methods how to overcome common study design challenges and how these affect your sample size calculations. In this webinar, we will use common issues in vaccine study design to examine difficulties surrounding issues such as:
Case-Control Analysis: We will examine how to deal with study constraints and how to deal with analyses done during an observational study.
Alternative Randomization Methods: How best to address randomization in your vaccine trial design when full randomization is difficult, expensive or impractical. We examine how sample size calculations are affected with cluster or Mendelian randomization.
Rare Events: How does an outcome being rare affect the types of study design and statistical methods chosen in your study.
Combination of informative biomarkers in small pilot studies and estimation ...LEGATO project
Background:
Biomarker candidates are defined as measurable molecules found in biological media. According to Biomarkers Definitions Working Group, 2001, biomarkers cover a rather wide range of parameters. Recently, biomarkers are used widely in medical researches, where single biomarkers may not possess the desired cause-effect association for disease classification and outcome prediction. Therefore the efforts of the researchers currently is to combine biomarkers. By new technologies like microarrays, next generation sequencing and mass spectrometry, researchers can obtain many biomarker candidates that can exceed tens of thousands. To avoid wasting money and time, it is suggested to control the number of patients strictly. However, pilot studies usually have low statistical power which reduces the chance of detecting a true effect .
Minimizing Risk In Phase II and III Sample Size CalculationnQuery
[ Watch Webinar: http://bit.ly/2thIgmi ]. In this free webinar, Head of Statistics at Statsols, Ronan Fitzpatrick, addresses the issues of reducing risk in Phase II/III sample size calculations. Topics covered will include:
Sample Size Determination For Different Trial Designs
Bayesian Sample Size Determination
Sample Size For Survival Analysis
& more
Large amounts of heterogeneous medical data have become available in various healthcare organizations (payers, providers, pharmaceuticals). Those data could be an enabling resource for deriving insights for improving care delivery and reducing waste. The enormity and complexity of these datasets present great challenges in analyses and subsequent applications to a practical clinical environment. More details are available here http://dmkd.cs.wayne.edu/TUTORIAL/Healthcare/
Sample size calculation in medical researchKannan Iyanar
A short description on estimation of sample size in health care research. It describes the basic concepts in sample size estimation and various important formulae used for it.
Workshop on "Building Successful Pipelines for Predictive Analytics in Healthcare" delivered by Danielle Belgrave, PhD, Researcher at Microsoft Research, Cambridge, UK.
Jimmy Gentry on 'Securities and Exchange Commission Filings" at Reynolds Business Journalism Week, Feb. 4-7, 2011.
Reynolds Center for Business Journalism, BusinessJournalism.org, Arizona State University's Walter Cronkite School of Journalism.
Similar to NY Prostate Cancer Conference - A. Vickers - Session 1: Traditional statistical methods for evaluating prediction models are uninformative: towards a decision analytic approach
Measuring clinical utility: uncertainty in Net BenefitLaure Wynants
Introduction and Objective(s)
The impact of introducing a prediction model in clinical practice to inform clinical decisions on interventions (eg. treat patient vs. do not treat patient) can be quantified by Net Benefit (NB). NB is calculated as TP/N - FP/N * w, where TP is the number of true positives, FP is the number of false positives, and w is a weight reflecting the benefit of a TP and the harm of a FP. NB and decision curves (where NB is plotted for a range of w) are population-level quantities that can tell policymakers whether using a prediction model is better than using alternative strategies (such as treat all or treat none). Nonetheless, the NB estimate itself is uncertain. The objective of this talk is to investigate the origins and measures of NB uncertainty.
Method(s) and Results
Sampling variability and heterogeneity between populations are sources of uncertainty about NB. We will show that despite wide confidence and prediction intervals around NB, the choice of optimal strategy may be unaffected. A first measure of uncertainty is the probability of usefulness. It is the probability that the model is the optimal strategy among competing strategies and can be calculated through a random effects meta-analysis. The probability of usefulness has conceptual links with a second measure, the Net Benefit Value of Information (NB VOI). VOI is a concept borrowed from decision theory that quantifies the expected loss due to not confidently knowing which of competing strategies is the best. The methods will be illustrated with case studies in ovarian cancer diagnosis and prognosis after myocardial infarction.
Conclusions
Uncertainty in NB can be large. The probability of usefulness from a random-effects meta-analysis reflects heterogeneity in clinical utility across populations, while the NB VOI can be used to determine whether more validation data from a certain population is needed.
Evidence based medicine is now focusing on diagnostic tests: how accurate and useful could be ? sensitivity and specificity are no longer the important criteria for a test
The ppt is a short description about how to ascertain the validity, ie; sensitivity and specificity of a screening test as well as their predictive powers. you can also find the technique to ascertain the best possible screening test through the help of an ROC curve...
Common statistical tests useful for biomedical scientists and research physicians.
Similar to NY Prostate Cancer Conference - A. Vickers - Session 1: Traditional statistical methods for evaluating prediction models are uninformative: towards a decision analytic approach (20)
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf91mobiles
91mobiles recently conducted a Smart TV Buyer Insights Survey in which we asked over 3,000 respondents about the TV they own, aspects they look at on a new TV, and their TV buying preferences.
Connector Corner: Automate dynamic content and events by pushing a buttonDianaGray10
Here is something new! In our next Connector Corner webinar, we will demonstrate how you can use a single workflow to:
Create a campaign using Mailchimp with merge tags/fields
Send an interactive Slack channel message (using buttons)
Have the message received by managers and peers along with a test email for review
But there’s more:
In a second workflow supporting the same use case, you’ll see:
Your campaign sent to target colleagues for approval
If the “Approve” button is clicked, a Jira/Zendesk ticket is created for the marketing design team
But—if the “Reject” button is pushed, colleagues will be alerted via Slack message
Join us to learn more about this new, human-in-the-loop capability, brought to you by Integration Service connectors.
And...
Speakers:
Akshay Agnihotri, Product Manager
Charlie Greenberg, Host
UiPath Test Automation using UiPath Test Suite series, part 4DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 4. In this session, we will cover Test Manager overview along with SAP heatmap.
The UiPath Test Manager overview with SAP heatmap webinar offers a concise yet comprehensive exploration of the role of a Test Manager within SAP environments, coupled with the utilization of heatmaps for effective testing strategies.
Participants will gain insights into the responsibilities, challenges, and best practices associated with test management in SAP projects. Additionally, the webinar delves into the significance of heatmaps as a visual aid for identifying testing priorities, areas of risk, and resource allocation within SAP landscapes. Through this session, attendees can expect to enhance their understanding of test management principles while learning practical approaches to optimize testing processes in SAP environments using heatmap visualization techniques
What will you get from this session?
1. Insights into SAP testing best practices
2. Heatmap utilization for testing
3. Optimization of testing processes
4. Demo
Topics covered:
Execution from the test manager
Orchestrator execution result
Defect reporting
SAP heatmap example with demo
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
UiPath Test Automation using UiPath Test Suite series, part 3DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 3. In this session, we will cover desktop automation along with UI automation.
Topics covered:
UI automation Introduction,
UI automation Sample
Desktop automation flow
Pradeep Chinnala, Senior Consultant Automation Developer @WonderBotz and UiPath MVP
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
The Art of the Pitch: WordPress Relationships and SalesLaura Byrne
Clients don’t know what they don’t know. What web solutions are right for them? How does WordPress come into the picture? How do you make sure you understand scope and timeline? What do you do if sometime changes?
All these questions and more will be explored as we talk about matching clients’ needs with what your agency offers without pulling teeth or pulling your hair out. Practical tips, and strategies for successful relationship building that leads to closing the deal.
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...UiPathCommunity
💥 Speed, accuracy, and scaling – discover the superpowers of GenAI in action with UiPath Document Understanding and Communications Mining™:
See how to accelerate model training and optimize model performance with active learning
Learn about the latest enhancements to out-of-the-box document processing – with little to no training required
Get an exclusive demo of the new family of UiPath LLMs – GenAI models specialized for processing different types of documents and messages
This is a hands-on session specifically designed for automation developers and AI enthusiasts seeking to enhance their knowledge in leveraging the latest intelligent document processing capabilities offered by UiPath.
Speakers:
👨🏫 Andras Palfi, Senior Product Manager, UiPath
👩🏫 Lenka Dulovicova, Product Program Manager, UiPath
Key Trends Shaping the Future of Infrastructure.pdfCheryl Hung
Keynote at DIGIT West Expo, Glasgow on 29 May 2024.
Cheryl Hung, ochery.com
Sr Director, Infrastructure Ecosystem, Arm.
The key trends across hardware, cloud and open-source; exploring how these areas are likely to mature and develop over the short and long-term, and then considering how organisations can position themselves to adapt and thrive.
Transcript: Selling digital books in 2024: Insights from industry leaders - T...BookNet Canada
The publishing industry has been selling digital audiobooks and ebooks for over a decade and has found its groove. What’s changed? What has stayed the same? Where do we go from here? Join a group of leading sales peers from across the industry for a conversation about the lessons learned since the popularization of digital books, best practices, digital book supply chain management, and more.
Link to video recording: https://bnctechforum.ca/sessions/selling-digital-books-in-2024-insights-from-industry-leaders/
Presented by BookNet Canada on May 28, 2024, with support from the Department of Canadian Heritage.
Essentials of Automations: Optimizing FME Workflows with ParametersSafe Software
Are you looking to streamline your workflows and boost your projects’ efficiency? Do you find yourself searching for ways to add flexibility and control over your FME workflows? If so, you’re in the right place.
Join us for an insightful dive into the world of FME parameters, a critical element in optimizing workflow efficiency. This webinar marks the beginning of our three-part “Essentials of Automation” series. This first webinar is designed to equip you with the knowledge and skills to utilize parameters effectively: enhancing the flexibility, maintainability, and user control of your FME projects.
Here’s what you’ll gain:
- Essentials of FME Parameters: Understand the pivotal role of parameters, including Reader/Writer, Transformer, User, and FME Flow categories. Discover how they are the key to unlocking automation and optimization within your workflows.
- Practical Applications in FME Form: Delve into key user parameter types including choice, connections, and file URLs. Allow users to control how a workflow runs, making your workflows more reusable. Learn to import values and deliver the best user experience for your workflows while enhancing accuracy.
- Optimization Strategies in FME Flow: Explore the creation and strategic deployment of parameters in FME Flow, including the use of deployment and geometry parameters, to maximize workflow efficiency.
- Pro Tips for Success: Gain insights on parameterizing connections and leveraging new features like Conditional Visibility for clarity and simplicity.
We’ll wrap up with a glimpse into future webinars, followed by a Q&A session to address your specific questions surrounding this topic.
Don’t miss this opportunity to elevate your FME expertise and drive your projects to new heights of efficiency.
GraphRAG is All You need? LLM & Knowledge GraphGuy Korland
Guy Korland, CEO and Co-founder of FalkorDB, will review two articles on the integration of language models with knowledge graphs.
1. Unifying Large Language Models and Knowledge Graphs: A Roadmap.
https://arxiv.org/abs/2306.08302
2. Microsoft Research's GraphRAG paper and a review paper on various uses of knowledge graphs:
https://www.microsoft.com/en-us/research/blog/graphrag-unlocking-llm-discovery-on-narrative-private-data/
NY Prostate Cancer Conference - A. Vickers - Session 1: Traditional statistical methods for evaluating prediction models are uninformative: towards a decision analytic approach
1.
2. The Kattan challenge A clinician comes to you with two models (or tests) and wants to know which to use. What statistical method do you use to help answer the clinician?
7. Prostate cancer Use of the model to determine treatment would avoid 47 unnecessary treatments at the expense of failing to treat 45 patients who do require treatment.
21. Application to models with a continuous endpoint 1. Select a p t 2. Positive test defined as 3. Calculate “Clinical Net Benefit” as:
22. Kallikrein panel: weight false positives by 20% ÷ (1 – 20%) Cancers found Unecessary Biopsies Net benefit Biopsy all men with elevated PSA 277 723 277 - 723 ÷ 4 96.25 Biopsy if risk ≥ 20% on panel 211 276 211 - 276 ÷ 4 142
23.
24.
25. Decision curve analysis 4. Vary p t over an appropriate range Vickers & Elkin Med Decis Making 2006;26:565–574 1. Select a p t 2. Positive test defined as 3. Calculate “Clinical Net Benefit” as:
31. Statistical analysis vs. decision analysis Traditional statistical analysis Traditional decision analysis Mathematics Simple Can be complex Additional data Not required Patient preferences, costs or effectiveness Endpoints Binary or continuous Continuous endpoints problematic Assess clinical value? No Yes
32. Statistical analysis vs. decision analysis Traditional statistical analysis Traditional decision analysis Decision curve analysis Mathematics Simple Can be complex Simple Additional data Not required Patient preferences, costs or effectiveness Informal, general estimates Endpoints Binary or continuous Continuous endpoints problematic Binary or continuous Assess clinical value? No Yes Yes